Certican derives Successful Result

.

Certican derives Successful Result

Surely, it was a good news for Novartis that it has been able to have positive result of its phase III clinical study of immune system drug known as Certican. The news was worth getting happy, as it has been found that the Swiss pharmaceutical company was trying to get everything right for last two years.

In addition, it has been said that the project is considered to be the biggest project that has been taken out by the company with regard to liver transplant. It has been found that the drug is quite effective in improving renal function among patients.

The data about the same was revealed at the meeting of American Association for the Study of Liver Diseases (AASLD), which is in its 63rd year. The drug, which has already received approval from European health authorities, is likely to get approval from the US health regulators Food and Drug Administration by the end of 2012.

"These results showed that treatment with Certican with reduced tacrolimus led to a clinically relevant retention of renal function compared to standard tacrolimus, with no compromise in rejection", said John Fung, who is positioned as director at Transplantation Center. It is expected that the drug is able to provide benefit to adults suffering from liver problem.


Latest News

Ford Shares Drop With Profit Concerns
Dominion LNG Export Project Gets Green Signal from FERC
Second Quarter Shows Fastest Growth of U.S Economy
Stronger Safeguarding Rules for Service Members Against Predatory Lenders
Yahoo Urged to Buy Rival AOL Inc.
Slowing Down of Inflation May Make it Difficult for BOJ to Achieve its Target
B.K. Modi’s CIO Plans to Start Pre-IPO Fund
American Soda makers Promise to Trim Twenty Percent Calories by 2025
Federal Reserve Bank of Dallas has Hired a Search Firm to Find Suitable Replacem
Stricter Rules on Tax Inversion Push Down Stocks of Firms Considering Such Moves
Brazilian President Says Growth in the U.S. Could Result in an Improvement of Br
Anonymous Whistleblower to get $30 Million from SEC